C-MYC-miRNA Circuitry: a Central Regulator of Aggressive B-cell Malignancies

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2014 Jan 8

PMID 24394940

Citations 30

Authors

Jiangchuan Tao

Xiaohong Zhao

Jianguo Tao

Affiliations

Soon will be listed here.

Abstract

MYC (c-Myc) deregulation has been frequently associated with aggressive lymphomas and adverse clinical outcome in B-cell malignancies. MYC has been implicated in controlling the expression of miRNAs, and MYC-regulated miRNAs affect virtually all aspects of the hallmarks of MYC-driven lymphomas. Increasing evidence has indicated that there is significant cross-talk between MYC and miRNAs, with MYC regulating expression of a number of miRNAs, resulting in widespread repression of miRNA and, at the same time, MYC being subjected to regulation by miRNAs, leading to sustained MYC activity and the corresponding MYC downstream pathways. Thus, these combined effects of MYC overexpression and downregulation of miRNAs play a central regulatory role in the MYC oncogenic pathways and MYC-driven lymphomagenesis. Here, we provide biological insight on the function of MYC-regulated miRNAs, the mechanisms of MYC-induced miRNA repression, and the complicated feedback circuitry underlying lymphoma progression, as well as potential therapeutic targets in aggressive B-cell lymphomas.

Citing Articles

microRNA Profile of High-Grade B-Cell Lymphoma with 11q Aberration.

Zajdel M, Szafron L, Paziewska A, Rymkiewicz G, Dabrowska M, Bystydzienski Z Int J Mol Sci. 2025; 26(1.

PMID: 39796140 PMC: 11720131. DOI: 10.3390/ijms26010285.

Integrated Transcriptomics and Network Analysis of Potential Mechanisms and Health Effects of Convalescent COVID-19 Patients.

Chujan S, Nakareangrit W, Suriyo T, Satayavivad J Bioinform Biol Insights. 2023; 17:11779322231206684.

PMID: 37881207 PMC: 10594973. DOI: 10.1177/11779322231206684.

Role of miR‑let‑7c‑5p/c‑myc signaling axis in the committed differentiation of leukemic THP‑1 cells into monocytes/macrophages.

Sun R, Wang C, Wang Y, Wu Y, Du P, Sun X Oncol Lett. 2023; 26(3):403.

PMID: 37600342 PMC: 10433716. DOI: 10.3892/ol.2023.13989.

Long noncoding RNA (lncRNA) HOTAIR: Pathogenic roles and therapeutic opportunities in gastric cancer.

Kong W, Yin G, Zheng S, Liu X, Zhu A, Yu P Genes Dis. 2022; 9(5):1269-1280.

PMID: 35873034 PMC: 9293693. DOI: 10.1016/j.gendis.2021.07.006.

A Set of 17 microRNAs Common for Brain and Cerebrospinal Fluid Differentiates Primary Central Nervous System Lymphoma from Non-Malignant Brain Tumors.

Sromek M, Rymkiewicz G, Paziewska A, Szafron L, Kulecka M, Zajdel M Biomolecules. 2021; 11(9).

PMID: 34572608 PMC: 8466839. DOI: 10.3390/biom11091395.

References

Chang T, Zeitels L, Hwang H, Chivukula R, Wentzel E, Dews M . Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc Natl Acad Sci U S A. 2009; 106(9):3384-9. PMC: 2651245. DOI: 10.1073/pnas.0808300106. View

Vita M, Henriksson M . The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol. 2006; 16(4):318-30. DOI: 10.1016/j.semcancer.2006.07.015. View

Eilers M, Eisenman R . Myc's broad reach. Genes Dev. 2008; 22(20):2755-66. PMC: 2751281. DOI: 10.1101/gad.1712408. View

Zhang X, Chen X, Lin J, Lwin T, Wright G, Moscinski L . Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene. 2011; 31(24):3002-3008. PMC: 3982396. DOI: 10.1038/onc.2011.470. View

Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S . A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008; 9(6):582-9. PMC: 2396950. DOI: 10.1038/embor.2008.74. View

Dang C . MYC on the path to cancer. Cell. 2012; 149(1):22-35. PMC: 3345192. DOI: 10.1016/j.cell.2012.03.003. View

Chang T, Yu D, Lee Y, Wentzel E, Arking D, West K . Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet. 2007; 40(1):43-50. PMC: 2628762. DOI: 10.1038/ng.2007.30. View

Wang F, Fu X, Zhou Y, Zhang Y . Down-regulation of the cyclin E1 oncogene expression by microRNA-16-1 induces cell cycle arrest in human cancer cells. BMB Rep. 2009; 42(11):725-30. PMC: 6604625. DOI: 10.5483/bmbrep.2009.42.11.725. View

Dang C, Le A, Gao P . MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res. 2009; 15(21):6479-83. PMC: 2783410. DOI: 10.1158/1078-0432.CCR-09-0889. View

10.

Slack G, Gascoyne R . MYC and aggressive B-cell lymphomas. Adv Anat Pathol. 2011; 18(3):219-28. DOI: 10.1097/PAP.0b013e3182169948. View

11.

Bui T, Mendell J . Myc: Maestro of MicroRNAs. Genes Cancer. 2010; 1(6):568-575. PMC: 2946068. DOI: 10.1177/1947601910377491. View

12.

Mogilyansky E, Rigoutsos I . The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ. 2013; 20(12):1603-14. PMC: 3824591. DOI: 10.1038/cdd.2013.125. View

13.

Lin C, Jackson A, Guo J, Linsley P, Eisenman R . Myc-regulated microRNAs attenuate embryonic stem cell differentiation. EMBO J. 2009; 28(20):3157-70. PMC: 2744176. DOI: 10.1038/emboj.2009.254. View

14.

Lin J, Lwin T, Zhao J, Tam W, Choi Y, Moscinski L . Follicular dendritic cell-induced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas. Leukemia. 2010; 25(1):145-52. PMC: 3083119. DOI: 10.1038/leu.2010.230. View

15.

Craig V, Cogliatti S, Imig J, Renner C, Neuenschwander S, Rehrauer H . Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood. 2011; 117(23):6227-36. PMC: 3790944. DOI: 10.1182/blood-2010-10-312231. View

16.

Hatzivassiliou G, Zhao F, Bauer D, Andreadis C, Shaw A, Dhanak D . ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell. 2005; 8(4):311-21. DOI: 10.1016/j.ccr.2005.09.008. View

17.

Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R . Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. Cancer Cell. 2012; 22(4):506-523. PMC: 3973134. DOI: 10.1016/j.ccr.2012.09.003. View

18.

Hernandez L, Hernandez S, Bea S, Pinyol M, Ferrer A, Bosch F . c-myc mRNA expression and genomic alterations in mantle cell lymphomas and other nodal non-Hodgkin's lymphomas. Leukemia. 1999; 13(12):2087-93. DOI: 10.1038/sj.leu.2401599. View

19.

Peter M . Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle. 2009; 8(6):843-52. PMC: 2688687. DOI: 10.4161/cc.8.6.7907. View

20.

Ivanovska I, Ball A, Diaz R, Magnus J, Kibukawa M, Schelter J . MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol. 2008; 28(7):2167-74. PMC: 2268421. DOI: 10.1128/MCB.01977-07. View